News

05.03.2019

Healthcare innovations gain traction with the DayOne Accelerator

Healthcare innovations gain traction with the DayOne Accelerator

Three innovative healthcare startups participate in the first round of the DayOne Accelerator. Faraz Oloumi from Aurteen, Chang Yun from Noul and Christian Vogler and Leo Gschwind from Advancience are examples of how far conviction can get you.

mehr >
20.03.2019

SpiroChem enters into partnership with UK’s Domainex

In future, UK drug discovery services company Domainex will be using molecular fragments from SpiroChem in its discovery work for new agents. As a result, it wants to increase hits for its clients.

mehr >
14.03.2019

Axovant offering common shares

Basel-based pharmaceutical company Axovant Sciences is commencing a public offering of its common shares. It expects to generate proceeds of US$40 million. Axovant is listed on the U.S. technology exchange NASDAQ.

mehr >
05.02.2019

“We are a small company with a big portfolio”

“We are a small company with a big portfolio”

After Martine and Jean-Paul Clozel created Actelion with two other founders and grew Actelion into Europe’s biggest biotech, the company and its late-stage pipeline were acquired by Johnson&Johnson in 2017. With Actelion’s discovery- and early-stage R&D assets, the couple formed Idorsia, with the vision to build one of Europe’s leading biopharmaceutical companies

mehr >
12.03.2019

Roche takes Switzerland to number one for patents

Roche takes Switzerland to number one for patents

In 2018, no other country in Europe saw more patents filed relative to population size than Switzerland. This has been found by a new report from the European Patent Office. The most Swiss patent applications come from the Basel pharmaceutical giant Roche.

mehr >
05.03.2019

«Le Tout Connecté 2019» a pris le pouls de la santé et de l’innovation

«Le Tout Connecté 2019» a pris le pouls de la santé et de l’innovation

La troisième édition de l’événement «Le Tout Connecté» s’est déroulée jeudi 28 février dernier à Delémont (JU) avec le thème «santé et innovation» --, mise sur pied par BaselArea.swiss, la Promotion économique du canton du Jura, Creapole, la Chambre de commerce et d’industrie du Jura (CCIJ), avec Raiffeisen Suisse comme partenaire principal.

mehr >
08.01.2019

"It doesn't always have to stay the same"

Désirée Mettraux has been the CEO of Creadi since 2016. The Pax spin-off has developed the Simpego online insurance platform. The insurance expert is confident that the industry will profit if it opens itself up to partners. The aim is to make insurance fun.

mehr >
05.03.2019

New at Switzerland Innovation Park Basel Area: SunRegen

New at Switzerland Innovation Park Basel Area: SunRegen

The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.

mehr >
04.03.2019

Computer science and medicine are coming together

Computer science and medicine are coming together

The University of Applied Sciences and Arts Northwestern Switzerland (FHNW) is launching a new Masters course in Medical Informatics. It will look at topics such as the synergy between internet-linked pacemakers and medical knowledge.

mehr >
03.12.2018

“Momentum for blockchain in healthcare is growing in Basel”

“Momentum for blockchain in healthcare is growing in Basel”

Marco Cuomo and Daniel Fritz from Novartis got engaged in blockchain two years ago. Today, their aim is set high: With other pharma companies under the Innovative Medicines Initiative, they formed a “Blockchain Enabled Healthcare” program, due to kick off in 2019. The program that they presented at the Blockchain Leadership Summit in Basel – Switzerland’s largest conference in this field - wants no less than to define how blockchain is applied in healthcare.

mehr >
27.02.2019

Basel offers the lowest corporate income tax of all major Swiss business centres

Basel offers the lowest corporate income tax of all major Swiss business centres

The Canton of Basel-Stadt has lowered its tax rates on income, corporate income and capital retroactively to 1 January 2019. Its corporate taxes will from now on be among the lowest in Switzerland and in Europe, making Basel even more attractive as a business location.

mehr >
27.02.2019

Aging: The Tsunami for Healthcare

From the left side: Thomas Brenzikofer (DayOne/ BaselArea.swiss), Szofia Bullain (MD Geriatric Neurologist), Antonella Santuccione (Woman’s Brain Project and Roche Diagnostics), Hansruedi Voelkle (EUPATI), Manfred Eggersdorfer, (DSM Nutritional Products), Andy Bushell (Novartis), Mieke Deschodt (University of Basel)

Humanity is growing older. According to the UN the number of people in the world aged 60 years or over is projected to double to 2.1 billion by 2050. In developed countries, more than one third of the population will be over 60 by this time. The number of people over 80 will increase even faster to 434 million from 125 million in 2017. Meanwhile the working age population, who are needed to pay or provide support for the elderly, will only increase by about 25 percent over the same time.

mehr >
23.11.2018

Expats like Basel best

Expats like Basel best

Expats find Basel to be the best city in Switzerland, according to a study published by InterNations. Six Swiss cities were analyzed as part of its latest Expat City Ranking.

mehr >
27.02.2019

Where diagnostic startups gain support

The diagnostics event "Startups and Startup Support", hosted by BaselArea.swiss in January focused on startups and startup support. Participants got to know organizations that specifically support diagnostics startups and new technologies in this field as well as beneficiaries like Resistell.

mehr >
26.02.2019

Anaveon raises CHF 35 million

Anaveon raises CHF 35 million

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch, the healthcare accelerator of BaselArea.swiss in December 2017 and in 2018 also raised additional seed money from the UZH Life Sciences Fund.

mehr >
14.11.2018

Roivant raised USD 200 million, now valued at USD 7 billion

Roivant raised USD 200 million, now valued at USD 7 billion

The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an estimated USD 7 billion.

mehr >
25.02.2019

Roche acquires Spark Therapeutics

Roche acquires Spark Therapeutics

Basel-based pharmaceutical Group Roche has agreed a takeover with US gene therapy company Spark Therapeutics. The total transaction value is US$ 4.3 billion.

mehr >
21.02.2019

First Blockchain professorship in Switzerland at University of Basel

First Blockchain professorship in Switzerland at University of Basel

Fabian Schär has taken on the first blockchain professorship at the University of Basel. In various interviews, he said that the impact of technology is being underestimated.

mehr >
05.11.2018

Three entrepreneurs, three visions of Industry 4.0

Dominik Trost (holo|one), Philippe Kapfer (NextDay.Vision), Roy Chikballapur (MachIQ)

BaselArea.swiss invited startups and Industry 4.0 projects to participate in the first Industry 4.0 Challenge. A jury from the industry chose three finalists: Philippe Kapfer with NextDay.Vision, Roy Chikballapur with MachIQ and Dominik Trost with holo|one. Learn more about their contributions and visions in the interview. You can meet the entrepreneurs at the Salon Industries du Futur Mulhouse on 20 and 21 November 2018.

mehr >
19.02.2019

Axovant spin-off acquires rights to antiepileptic drug

The new Basel company Arvelle Therapeutics has received one of the largest initial financing commitments for a European-focused biopharmaceutical company. As a result, it has been able to acquire the rights to develop and commercialize a new antiepileptic drug.

mehr >
11.02.2019

Basel-Stadt cuts taxes

Basel-Stadt cuts taxes

Citizens have approved the Basel compromise on corporation tax by a clear majority. The effective corporate income tax rate at the federal and cantonal levels including municipalities will drop to 13 percent, and capital tax rate to 0.1 percent. Income tax will fall as well, whereas deductions for health insurance payments will be raised.

mehr >
27.09.2018

"I Was Always One of Few Women in the Industry"

SOLO Swiss in Porrentruy in the canton of Jura has been making industrial furnaces for heat-treating metals since 1924. The family company with a global presence is developing against the backdrop of Industry 4.0 and is struggling to find the qualified workforce which is indispensable for what it does amid the effects of the strong franc and what are sometimes restrictive administrative regulations. Interview with Anne-Sophie Spérison, President and CEO.

mehr >
07.02.2019

Switzerland – a magnet in the global war for the best talents in Life Sciences

Switzerland – a magnet in the global war for the best talents in Life Sciences

It’s a sector of great importance for the Swiss national economy: The growing Life Science industry. Across pharmaceuticals, biotech, medtech, diagnostics or providing sectors more and more companies have settled in Switzerland over the last 15 years. In fact, the number of employees working in the pharmaceuticals sector almost doubled over the past 35 years reaching 46,000 in 2016. Some 33,500 work in the Basel region, the hometown of the two largest Swiss pharmaceutical companies Novartis and Roche which are among the most successful innovators of groundbreaking therapies on a global scale. Numerous upcoming Life Science companies such as Roivant have settled in Basel in recent years and international headquarters (global and regional) of renowned bio-pharma, consumer healthcare and medical medtech firms are expanding. This positive development is underpinned by new knowledge driven platforms focusing on precision medicine, biomaterial engineering and other domains.

mehr >
07.02.2019

Idorsia reports outstanding progress

Idorsia reports outstanding progress

Pharma research company Idorsia has completed its first full financial year. Chief Executive Officer Jean-Paul Clozel feels the company has made outstanding progress. Demerger activities were completed with the spin out from Actelion.

mehr >
04.09.2018

“Our business is the most beautiful business in the world”

“Our business is the most beautiful business in the world”

Giacomo di Nepi has a successful history: A high level executive in big corporations, he transitioned towards biotech, currently as CEO of Polyphor, which, in May 2018, he led to the IPO. We spoke to Giacomo about serving patients, the timing for an IPO and the people needed in a biotech.

mehr >
05.02.2019

Redesigning Healthcare - Das war die Future Health 2019

In der Gesundheitslandschaft der Zukunft steht der Patient im Mittelpunkt. Das zeigte auch die Future Health 2019 in Basel, die Ende Januar 350 Gäste anzog. Unter dem Titel "Redesigning Healthcare" diskutierten über 20 Referentinnen und Referenten über das Gesundheitssystem der Zukunft.

mehr >
05.02.2019

Polyphor awarded grant for antibiotic

Polyphor awarded grant for antibiotic

Pharmaceutical company Polyphor is developing a novel antibiotic against the deadliest and most resistant Gram-negative bacterial pathogens. It has been awarded a grant of up to US$5.6 million to continue this work.

mehr >
15.07.2018

Basel pharma companies invest most in R&D

Basel pharma companies invest most in R&D

The 24 Interpharma companies spent a total of 96 billion Swiss francs on research and development worldwide in 2017. Of this, 7 billion francs were invested in Switzerland. When compared with the sales they generated in Switzerland, the companies’ Swiss research investment was more than twice as high. According to the association, this is a testament to the great significance of Switzerland as a research location and the innovation taking place at these companies.

mehr >
05.02.2019

BaseLaunch funds four healthcare ventures

BaseLaunch funds four healthcare ventures

BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.

mehr >
04.02.2019

Grosspeter Tower – Basel’s sustainable model skyscraper

Grosspeter Tower – Basel’s sustainable model skyscraper

With the ambitious goal of being a zero-emission building, Basel’s youngest skyscraper Grosspeter Tower was constructed to cover its own power requirements. Already during the construction phase, this impressive 78 meter office building by Burckhardt+Partner was awarded numerous prizes for its unique sustainable design and its building fabric. In particular, the façade, which is half windows, half integrated photovoltaic system - the first of its kind in Europe – make the building an efficient powerhouse.

mehr >
13.07.2018

Basel has the biggest economic potential

Basel has the biggest economic potential

Basel has the biggest economic potential in Europe, according to a new study from BAK Economics. The city on the bend of the Rhine ranked particularly well for competitiveness, while Geneva and Zurich also came in the top five.

mehr >
04.02.2019

DayOne Catalyst Project: Oonida

DayOne Catalyst Project: Oonida

One of the pillars of BaselArea.swiss’ DayOne (www.DayOne.swiss) strategy is to drive Catalyst projects – collaborative approaches to bottleneck issues in Healthcare innovation. These are “wicked problems” that can only be solved collaboratively. Therefore, Catalyst Projects focus on challenges to which it is difficult to find solutions within the current industry structures.

mehr >
01.02.2019

Basel-Stadt ranked top for accessibility

Basel-Stadt ranked top for accessibility

According to the BAK Accessibility Index, Basel-Stadt was again one of the most easily accessible Swiss cantons in 2018. This applies to both motorized private transport and public transport connections.

mehr >
03.07.2018

"Processes Kill Innovation"

The serial entrepreneur Neil Goldsmith is drawn to new ventures. We spoke to him about discovering talent suitable for start-ups and about his current involvement with BaseLaunch.

mehr >
29.01.2019

Basilea and Roche join forces to fight cancer

Basilea and Roche, two Basel-based pharmaceutical companies, have entered into a collaboration. Drugs from the two companies will be used in combination to explore treatment for patients with urothelial cancer.

mehr >
21.01.2019

Novartis tests low-volume factory for pharmaceuticals

Novartis tests low-volume factory for pharmaceuticals

In future pharmaceuticals could be manufactured in small factories that combine all the work steps from the raw material to pill production in one room. Novartis is testing the new method in Basel. It saves time and enables the development of new medicines.

mehr >
17.06.2018

Most exciting biotechs are based in Basel

Biotechs based in Basel

Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion and Polyphor.

mehr >
17.01.2019

Novartis leads the way in Swiss record-breaking transactions

Novartis leads the way in Swiss record-breaking transactions

The number of mergers and acquisitions by Swiss companies reached a new high in 2018. Transaction volume rose compared to the previous year, but it still fell short of the record set in 2014. Novartis was involved in two of the biggest transactions.

mehr >
14.01.2019

Basel researchers identify drug against the formation of metastasis

Basel researchers identify drug against the formation of metastasis

Scientists from the University of Basel and the University Hospital of Basel have discovered a drug that suppresses the formation of metastases. Metastases are reponsible for 90% of all cancer-related fatalities.

mehr >
11.06.2018

“Basel has all the ingredients required to host a successful company”

“Basel has all the ingredients required to host a successful company”

The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured in Basilea’s annual report she talks about current challenges in oncology.

mehr >

 

(Source: http://www.baselarea.swiss/en/baselarea-swiss/channels/innovation-report.html)